264 related articles for article (PubMed ID: 17275129)
21. Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling.
Kim N; Kim CH; Ahn DW; Lee KS; Cho SJ; Park JH; Lee MK; Kim JS; Jung HC; Song IS
J Gastroenterol Hepatol; 2009 Mar; 24(3):480-7. PubMed ID: 18823436
[TBL] [Abstract][Full Text] [Related]
22. AMPK interacts with β-catenin in the regulation of hepatocellular carcinoma cell proliferation and survival with selenium treatment.
Park SY; Lee YK; Kim HJ; Park OJ; Kim YM
Oncol Rep; 2016 Mar; 35(3):1566-72. PubMed ID: 26707164
[TBL] [Abstract][Full Text] [Related]
23. The anti-proliferative potency of celecoxib is not a class effect of coxibs.
Schiffmann S; Maier TJ; Wobst I; Janssen A; Corban-Wilhelm H; Angioni C; Geisslinger G; Grösch S
Biochem Pharmacol; 2008 Jul; 76(2):179-87. PubMed ID: 18547544
[TBL] [Abstract][Full Text] [Related]
24. The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism.
Lampiasi N; Azzolina A; Umezawa K; Montalto G; McCubrey JA; Cervello M
Cancer Lett; 2012 Sep; 322(1):35-44. PubMed ID: 22343223
[TBL] [Abstract][Full Text] [Related]
25. siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival.
Zeng G; Apte U; Cieply B; Singh S; Monga SP
Neoplasia; 2007 Nov; 9(11):951-9. PubMed ID: 18030363
[TBL] [Abstract][Full Text] [Related]
26. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer.
Tuynman JB; Vermeulen L; Boon EM; Kemper K; Zwinderman AH; Peppelenbosch MP; Richel DJ
Cancer Res; 2008 Feb; 68(4):1213-20. PubMed ID: 18281498
[TBL] [Abstract][Full Text] [Related]
27. COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Majchrzak-Celińska A; Misiorek JO; Kruhlenia N; Przybyl L; Kleszcz R; Rolle K; Krajka-Kuźniak V
BMC Cancer; 2021 May; 21(1):493. PubMed ID: 33941107
[TBL] [Abstract][Full Text] [Related]
28. Down-regulation of PGE2 by physiologic levels of celecoxib is not sufficient to induce apoptosis or inhibit cell proliferation in human colon carcinoma cell lines.
Lev-Ari S; Kazanov D; Liberman E; Ben-Yosef R; Arber N
Dig Dis Sci; 2007 Apr; 52(4):1128-33. PubMed ID: 17342386
[TBL] [Abstract][Full Text] [Related]
29. The inhibitory effect of celecoxib on mouse hepatoma H22 cell line on the arachidonic acid metabolic pathway.
Xu Z; Zhang M; Lv X; Xiang D; Zhang X; Chen L
Biochem Cell Biol; 2010 Aug; 88(4):603-9. PubMed ID: 20651831
[TBL] [Abstract][Full Text] [Related]
30. The effect and mechanism of bufalin on regulating hepatocellular carcinoma cell invasion and metastasis via Wnt/β-catenin signaling pathway.
Gai JQ; Sheng X; Qin JM; Sun K; Zhao W; Ni L
Int J Oncol; 2016 Jan; 48(1):338-48. PubMed ID: 26648168
[TBL] [Abstract][Full Text] [Related]
31. Interferon-α and cyclooxygenase-2 inhibitor cooperatively mediates TRAIL-induced apoptosis in hepatocellular carcinoma.
Zuo C; Qiu X; Liu N; Yang D; Xia M; Liu J; Wang X; Zhu H; Xie H; Dan H; Li Q; Wu Q; Burns M; Liu C
Exp Cell Res; 2015 May; 333(2):316-326. PubMed ID: 25724899
[TBL] [Abstract][Full Text] [Related]
32. Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth.
Bozzo F; Bassignana A; Lazzarato L; Boschi D; Gasco A; Bocca C; Miglietta A
Chem Biol Interact; 2009 Dec; 182(2-3):183-90. PubMed ID: 19682443
[TBL] [Abstract][Full Text] [Related]
33. Cyclooxygenase-2 inhibitor and interferon-beta synergistically induce apoptosis in human hepatoma cells in vitro and in vivo.
Nakamoto N; Higuchi H; Kanamori H; Kurita S; Tada S; Takaishi H; Toda K; Yamada T; Kumagai N; Saito H; Hibi T
Int J Oncol; 2006 Sep; 29(3):625-35. PubMed ID: 16865278
[TBL] [Abstract][Full Text] [Related]
34. Celecoxib-induced degradation of T-cell factors-1 and -4 in human colon cancer cells.
Takahashi-Yanaga F; Yoshihara T; Jingushi K; Miwa Y; Morimoto S; Hirata M; Sasaguri T
Biochem Biophys Res Commun; 2008 Dec; 377(4):1185-90. PubMed ID: 18983819
[TBL] [Abstract][Full Text] [Related]
35. Bufalin, a component in Chansu, inhibits proliferation and invasion of hepatocellular carcinoma cells.
Qiu DZ; Zhang ZJ; Wu WZ; Yang YK
BMC Complement Altern Med; 2013 Jul; 13():185. PubMed ID: 23870199
[TBL] [Abstract][Full Text] [Related]
36. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
[TBL] [Abstract][Full Text] [Related]
37. Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma.
Abrahão AC; Giudice FS; Sperandio FF; Pinto Junior Ddos S
J Oral Pathol Med; 2013 Nov; 42(10):793-8. PubMed ID: 23679684
[TBL] [Abstract][Full Text] [Related]
38. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo.
Wei W; Chua MS; Grepper S; So S
Int J Cancer; 2010 May; 126(10):2426-36. PubMed ID: 19662654
[TBL] [Abstract][Full Text] [Related]
39. [Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on growth and angiogenesis of human liver cancer HepG2 cell xenografts in small nude mice].
Zuo CH; Li ZR; Zhou X; Ouyang YZ; Zhou ZY; Zeng L
Ai Zheng; 2006 Apr; 25(4):414-20. PubMed ID: 16613672
[TBL] [Abstract][Full Text] [Related]
40. Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line.
Roy KR; Reddy GV; Maitreyi L; Agarwal S; Achari C; Vali S; Reddanna P
Cancer Chemother Pharmacol; 2010 Apr; 65(5):903-11. PubMed ID: 19685055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
